ATRC-101,Pembrolizumab
Atreca,merck
['solid tumor']
$bcel atreca presents data from ongoing phase 1b study of atrc-101 in patients with select advanced solid tumors during oral abstract session at the asco 2023 annual meeting #clinicaltrial#investing #trading 
Stay ahead of the market with ultra-fast stock news updates. 
FREE with 15 sec delay. Upgrade to Gold for even faster news & exclusive features @ https://t.co/LViEqnfZ7i